242 related articles for article (PubMed ID: 28104127)
1. Calcineurin Inhibitor-Induced Pain Syndrome in ABO-Incompatible Living Kidney Transplantation: A Case Report.
Ishida S; Kato M; Fujita T; Funahashi Y; Sassa N; Matsukawa Y; Yoshino Y; Yamamoto T; Katsuno T; Maruyama S; Gotoh M
Transplant Proc; 2017; 49(1):163-166. PubMed ID: 28104127
[TBL] [Abstract][Full Text] [Related]
2. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of high-dose mizoribine in ABO-incompatible kidney transplantation using anti-CD20 and anti-CD25 antibody without splenectomy treatment.
Yoshimura N; Ushigome H; Matsuyama M; Nobori S; Suzuki T; Sakai K; Okajima H; Okamoto M
Transplant Proc; 2012 Jan; 44(1):140-3. PubMed ID: 22310599
[TBL] [Abstract][Full Text] [Related]
4. Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model.
Jones-Hughes T; Snowsill T; Haasova M; Coelho H; Crathorne L; Cooper C; Mujica-Mota R; Peters J; Varley-Campbell J; Huxley N; Moore J; Allwood M; Lowe J; Hyde C; Hoyle M; Bond M; Anderson R
Health Technol Assess; 2016 Aug; 20(62):1-594. PubMed ID: 27578428
[TBL] [Abstract][Full Text] [Related]
5. Conversion of stable ABO-incompatible kidney transplant recipients from mycophenolate mofetil with standard exposure calcineurin inhibitors (CNIs) to everolimus with very low exposure CNIs-a short-term pilot study.
Uchida J; Machida Y; Iwai T; Kuwabara N; Kabei K; Naganuma T; Kumada N; Kawashima H; Nakatani T
Clin Transplant; 2014 Jan; 28(1):80-7. PubMed ID: 24329776
[TBL] [Abstract][Full Text] [Related]
6. Acute Inflammatory Syndrome Paradoxically Induced by De Novo Purine Inhibitors Synthesis Before Renal Transplantation: A Case Report and Review of the Literature.
Maruyama Y; Sadahira T; Mitsui Y; Wada K; Tanimoto R; Nishimura S; Kobayashi Y; Watanabe T; Nasu Y; Araki M
Transplant Proc; 2018 Apr; 50(3):895-897. PubMed ID: 29571743
[TBL] [Abstract][Full Text] [Related]
7. Long-term desensitization for ABO-incompatible living related kidney transplantation recipients with high refractory and rebound anti-blood type antibody: case report.
Nishimura H; Yamada Y; Hisano S; Mitsuke A; Tatarano S; Gotanda T; Hayami H; Nakagawa M; Enokida H
BMC Nephrol; 2018 Oct; 19(1):254. PubMed ID: 30290778
[TBL] [Abstract][Full Text] [Related]
8. Mycophenolate mofetil in pediatric renal transplantation: non-induction vs. induction with basiliximab.
Ojogho O; Sahney S; Cutler D; Baron PW; Abdelhalim FM; James S; Zuppan C; Franco E; Concepcion W
Pediatr Transplant; 2005 Feb; 9(1):80-3. PubMed ID: 15667617
[TBL] [Abstract][Full Text] [Related]
9. Excellent outcome of ABO-incompatible living kidney transplantation under pretransplantation immunosuppression with tacrolimus, mycophenolate mofetil, and steroid.
Tanabe K; Tokumoto T; Ishida H; Ishikawa N; Miyamoto N; Kondo T; Shimmura H; Setoguchi K; Toma H
Transplant Proc; 2004 Sep; 36(7):2175-7. PubMed ID: 15518791
[TBL] [Abstract][Full Text] [Related]
10. High-dose mizoribine combined with calcineurin inhibitor (cyclosporine or tacrolimus), basiliximab and corticosteroids for renal transplantation: A Japanese multicenter study.
Nishioka T; Yoshimura N; Ushigome H; Watarai Y; Nishimura K; Akioka K; Nakamura N; Kawakita M; Yuzawa K; Nakatani T
Int J Urol; 2018 Feb; 25(2):141-145. PubMed ID: 29068092
[TBL] [Abstract][Full Text] [Related]
11. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation.
Vacher-Coponat H; Moal V; Indreies M; Purgus R; Loundou A; Burtey S; Brunet P; Moussi-Frances J; Daniel L; Dussol B; Berland Y
Transplantation; 2012 Feb; 93(4):437-43. PubMed ID: 22228415
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppressive therapy for kidney transplantation in children and adolescents: systematic review and economic evaluation.
Haasova M; Snowsill T; Jones-Hughes T; Crathorne L; Cooper C; Varley-Campbell J; Mujica-Mota R; Coelho H; Huxley N; Lowe J; Dudley J; Marks S; Hyde C; Bond M; Anderson R
Health Technol Assess; 2016 Aug; 20(61):1-324. PubMed ID: 27557331
[TBL] [Abstract][Full Text] [Related]
13. Comparative study of clinical outcome in kidney transplantation between early steroid withdrawal protocol using basiliximab, calcineurin inhibitor, and mycophenolate mofetil and triple regimen consisting of calcineurin inhibitor, mycophenolate mofetil, and steroid.
Teraoka S; Sato S; Sekijima M; Iwado K; Urashima Y; Kudo S; Kai K; Koyama I; Tojinbara T; Nakajima I; Fuchinoue S
Transplant Proc; 2005 Mar; 37(2):791-4. PubMed ID: 15848533
[TBL] [Abstract][Full Text] [Related]
14. Impact of type of calcineurin inhibitor on post-transplant tuberculosis: Single-center study from India.
Agarwal SK; Bhowmik D; Mahajan S; Bagchi S
Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27775825
[TBL] [Abstract][Full Text] [Related]
15. Results of kidney transplantation in patients receiving MMF- or MMF and basiliximab-containing immunosuppression.
Tojimbara T; Nakajima I; Sato S; Nakamura M; Kawase T; Kai K; Tsuda S; Kudo S; Fuchinoue S; Teraoka S
Transplant Proc; 2004 Sep; 36(7):2087-9. PubMed ID: 15518755
[TBL] [Abstract][Full Text] [Related]
16. Side effects and efficacy of renal sparing immunosuppression in pediatric liver transplantation-A single center matched cohort study.
Leiskau C; Rajanayagam J; Pfister ED; Goldschmidt I; Junge N; Karch A; Lerch C; Richter N; Lehner F; Schrem H; Baumann U
Pediatr Transplant; 2018 Aug; 22(5):e13207. PubMed ID: 29729061
[TBL] [Abstract][Full Text] [Related]
17. Alemtuzumab induction in deceased donor kidney transplantation.
Huang E; Cho YW; Hayashi R; Bunnapradist S
Transplantation; 2007 Oct; 84(7):821-8. PubMed ID: 17984833
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of Tacrolimus without Basiliximab in Well-Matched Living-Donor Renal Transplant Recipients in Korea.
Baek CH; Kim JH; Yu H; Shin E; Cho H; Kim H; Yang WS; Han DJ; Park SK
Exp Clin Transplant; 2016 Aug; 14(4):389-93. PubMed ID: 27228054
[TBL] [Abstract][Full Text] [Related]
19. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
Favi E; Spagnoletti G; Salerno MP; Pedroso JA; Romagnoli J; Citterio F
Clin Transplant; 2013; 27(4):E359-67. PubMed ID: 23710603
[TBL] [Abstract][Full Text] [Related]
20. Initial experience with ABO-incompatible live donor renal transplantation.
Tsai MK; Wu MH; Lo SC; Lai IR; Yu SC; Yuan RH; Lee PH
J Formos Med Assoc; 2006 Sep; 105(9):775-9. PubMed ID: 16959628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
